New 'Smart Bomb' drug seeks to target multiple advanced cancers
NCT ID NCT06465069
Summary
This is a first-in-human study to test the safety and find the right dose of a new investigational drug called LY4052031 for people with advanced or metastatic solid tumors. The drug is designed to target a specific protein found on many cancer cells, delivering its medicine directly to the tumor. The study will enroll about 420 participants with various cancers, including bladder, breast, lung, and ovarian cancers, who have few or no other standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aichi Cancer Center Hospital
RECRUITINGNagoya, 464-8681, Japan
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
-
Catalan Institute of Oncology Duran i Reynals Hospital
RECRUITINGBarcelona, 8908, Spain
-
City of Hope National Medical Center
RECRUITINGDuarte, California, 91010-0269, United States
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032-3729, United States
-
Florida Cancer Specialists and Research Institute
RECRUITINGSt. Petersburg, Florida, 33705, United States
-
Hospital Madrid Norte Sanchinarro
RECRUITINGMadrid, 28050, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Hospital Universitario Virgen Del Rocio
RECRUITINGSeville, 41013, Spain
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029-6574, United States
-
Institut Gustave Roussy (Igr)
RECRUITINGVillejuif, 94805, France
-
Linear Clinical Research
RECRUITINGNedlands, 6009, Australia
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02215, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
National Cancer Center Hospital East
RECRUITINGKashiwa, Chiba, 277-8577, Japan
-
START Midwest Cancer and Hematology Centers of W Michigan
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute at HealthOne
RECRUITINGDenver, Colorado, 80218, United States
-
South Texas Accelerated Research Therapeutics (START)
RECRUITINGSan Antonio, Texas, 78229, United States
-
St Bartholomew's Hospital
RECRUITINGLondon, EC1A 7BE, United Kingdom
-
St Vincent's Hospital
RECRUITINGDarlinghurst, 2010, Australia
-
The Cancer Institute Hospital of JFCR
RECRUITINGKōtō City, 135-8550, Japan
-
The Christie NHS Foundation Trust
RECRUITINGManchester, M20 4BX, United Kingdom
-
University of Chicago Hospital
RECRUITINGChicago, Illinois, 60637, United States
-
University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030-4000, United States
-
University of Utah - Huntsman Cancer Institute
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Washington University School of Medicine in St. Louis
RECRUITINGSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.